The United Kingdom and the United States have agreed to a major bilateral deal that will maintain zero tariffs on British drug exports entering the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has pledged to boost expenditure on medicines through the public health system. This move guarantees that tariffs on these vital products will be held at nothing for a duration of the next three years.
This development is in response to previous statements to hike tariffs on patented pharmaceutical imports, with figures floated as high as one hundred percent.
"This deal between the UK strengthens the worldwide climate for cutting-edge drugs and establishes much-needed balance to transatlantic drug exports," an announcement declared.
Trade Significance
Medicines represent one of the Britain's biggest goods shipped to the US, which is clearly the largest market for leading UK drugmakers.
Trade data indicate that in the 12 months leading up to September, the UK exported medicines totaling over eleven billion pounds to the US. This figure made up a significant portion of all goods exports in that timeframe.
"This agreement protects employment, stimulates capital expenditure and facilitates the UK to become a worldwide center for medical research," a government official stated.
Specific NHS Changes
The deal includes several specific pledges from the United Kingdom:
- Revised Affordability Limit: The UK will raise the affordability limit at which it deems new treatments to be unaffordable by 25%.
- Boosted Medicine Funding: There is a aim to raise total public funding on drugs from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount drug companies must pay back to the NHS to stay within budget will be restricted at fifteen percent. Last year, rebates topped twenty percent.
Industry Background
The deal follows a ongoing dispute between the drug companies and the British authorities over spending levels and regulatory access.
The disagreement were heightened by claims that US patients were paying several times more for the identical medicines than consumers in the Britain and the EU.
Recently, several significant manufacturing plans in the UK have been delayed or cancelled, while substantial investments have been announced toward US facilities.
The Science Minister stated that the NHS had to spend more on medicines, noting that its budget allocation on drugs had shrunk as a percentage of its overall budget over the previous ten-year period.
